I’m curious to hear from people with a master’s degree who are working as biostatisticians in pharma or CROs. Compared with PhD-level biostatisticians, have you felt any differences in day-to-day work, promotion opportunities, leadership roles, technical expectations, or limitations in career growth?

I’m planning to apply for PhD programs this coming fall, and I currently hold a master’s degree in biostatistics. In almost every interview I’ve had, I’ve been asked why I didn’t pursue a PhD, so it’s made me think more seriously about if a PhD is something I may actually need if I want to work as a biostatistician long term.

At this point, I don’t have much research experience, and my interest is more in clinical trials and study design than in programming-heavy roles. At the same time, I know there are also people with master’s degrees who do work successfully as biostatisticians in pharma or CRO settings.

So before I apply to PhD programs, I’d really like to hear from people already in the field. In real-world work, what are the main differences between master’s-level and PhD-level biostatisticians in pharma or CROs? Are there clear differences in responsibilities, promotion opportunities, involvement in study design, leadership, or long-term career growth?

If you have a master’s degree and are working in this space, I’d especially love to hear about any limitations or challenges you’ve run into.

Thanks so much!

[ Removed by Reddit on account of violating the content policy. ]

I'm a biostats researcher, and every few years I'd notice the same pattern in myself and in people I taught: you learn this stuff once for an exam or a paper, then six months later you can't remember which test handles paired ordinal data, or what a confidence interval actually means vs. what you tell yourself it means.

So I built BioStat Quest — a case-based trainer that runs on spaced repetition. 50 cases, each wrapped around a realistic scenario (an ER triage audit, a clinical trial, a genetics study), with ~20 questions per case that drill the concept from different angles. When you get something wrong — or even when you get it right but shakily — the scheduler (FSRS-6, the same algorithm Anki uses) decides when to show it to you again.

Fast-forward a few weeks and the things you actually struggle with show up more often than the things you know cold.

What's different from most stats courses / YouTube series:

- It's active, not passive. You're answering board-style MCQs, not watching.

- It tracks your forgetting curve, not a fixed syllabus.

- Every wrong answer opens a "deep dive" that explains the concept, not just the right letter.

Who it's for: residents, MPH students, early-career researchers, anyone who needs biostats to stick.

Free, no signup required to play the first handful of cases. It runs in the browser — no install.

https://biostatquest.com

https://preview.redd.it/l3nnwfayu6wg1.png?width=1632&format=png&auto=webp&s=bc4802d1413a737bce04f036e5c400932855e697

I'd love feedback, especially on question quality and places where the explanations are unclear. There's a report button on every question.

Hi everyone,

I’m working on an RNA-seq dataset with three different drug treatments (let’s call them C, D, and E) and I’m trying to understand whether drug C acts differently from the other two, and if so, in what way.

I’m using a standard limma-voom pipeline and I’m a bit unsure about the best strategy to define contrasts for this question.

Current approaches I’m considering:

1. Pairwise contrasts + intersection

• C vs D
• C vs E Then:
• identify DE genes in each contrast
• take the intersection (possibly also requiring same direction of logFC)

The idea would be that genes consistently different in both contrasts represent a “C-specific signature”.

2. Combined contrast

• C − (D + E) / 2

This would directly test whether C differs from the average effect of D and E.

From a statistical and biological interpretation standpoint, which approach is more appropriate for identifying C-specific effects?

Any advice or references would be really appreciated.

Thanks in advance!

I'm building a composite health index that combines periodic blood biomarker data (every 4-12 weeks) with continuous wearable sensor data (daily) into domain-level health scores. After an external methodology review, I've resolved some initial issues but have new questions. Context:

What I've settled:

• Evidence weights from per-SD mortality hazard ratios (all HRs converted to per-SD scale before computing ln(HR))
• Reliability weights from CCC/ICC (not MAPE — switched after review showed MAPE conflates systematic bias with random noise)
• Geometric mean combination: √(We × Wr) — confirmed as defensible by reviewer
• Four independent health domains (no composite average across domains)

Where I need help:

1. Blood-wearable signal non-independence. In my metabolic domain, blood HbA1c and wearable step counts both encode insulin sensitivity signal. Google's WEAR-ME study (Nature 2026) showed wearable features explain 43% of HOMA-IR variance. I blend blood and wearable into one domain score with time-decaying weights (blood dominant when fresh, wearable dominant when blood is stale). Should I apply a correlation discount when the two signals share latent variance? If r(blood_score, wearable_score) > 0.45, what's the principled adjustment — reduce effective contribution by r/2? Or is there a better approach from multivariate composite construction?
2. Regression to the mean in a pre-post health monitoring system. Users who start monitoring because they feel unwell will have systematically worse baselines. Even without intervention, their scores will improve on retest. I'm planning ANCOVA correction (Corrected_gain = Observed_gain - (1-r_test-retest) × (Baseline - Pop_mean)) for backend analytics. Is ANCOVA sufficient, or should I also use Lord's paradox–aware methods? And in the user-facing display: should I suppress trend interpretation for the first 2 test cycles, or show it with a caveat?
3. Single-marker domain precision. One of my domains has only one blood marker (an inflammatory biomarker with intra-individual CV ≈ 44%, ICC ≈ 0.62). After log-transformation, effective ICC improves to ~0.70-0.75. I display a confidence band on this domain's score. Is there a minimum reliability threshold below which a single-marker domain score should not be shown at all? Or is the confidence band approach sufficient for a wellness (non-diagnostic) product?
4. Collinearity within a domain. Two of three blood markers in my metabolic domain share variance by design (one is mathematically derived from the other). VIF analysis is planned. If VIF > 2.5, should I discount the derived marker's weight, or is the intentional emphasis on the shared signal (glycemic control) defensible if clinically motivated?
5. Score normalization reference. I'm using a large US population survey (N=7,840) for age/sex-stratified z-scores. My target users are health-conscious Europeans aged 30-55 (BMI <27, no diabetes). What's the minimum overlap between reference and target population before normalization becomes misleading? Is sub-sampling the reference to match the target profile the right approach, or does that introduce selection bias?

After getting a bit tired of the constant stream of agentic AI/vibe-coding/context engineering/harness engineering content, I started to move into some relatively lesser explored areas in statistics- that's how I stumbled into survival analysis.

This is an ongoing blog series built from first principles. The emphasis is on actual mathematics of time-to-event modeling. It's not a "5-minute intro to survival analysis" or "Learn time-to-event modeling in 10 days using Python and lifelines".

If you like mathematical explanations, you may actually enjoy it.

Here's the series link- Articles – Madhav’s Blog

Here's one part- Part 3: Fitting Survival Distributions to Data – Madhav’s Blog

I am open to feedback and suggestions.

Disclaimer: I used Claude and ChatGPT for structuring/editing/proof-reading; the core ideas are mine.

The stats for scientists summer course filled up at my university, and I am trying to find somewhere else to take it. Does anyone have any recommendations for less expensive summer online stats courses in the US?

How far does the ranking usually move for Medicine at Maastricht (309 spots)? I’m ranked 370 — do I still have a chance? I would really appreciate any experiences, estimates, or past data 🙏

Has anyone heard back from UCI ISI BUDS yet?